Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis

26. mai 2026 oppdatert av: RenJi Hospital

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)

A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Studieoversikt

Detaljert beskrivelse

Acute deep venous thrombosis (DVT) is associated with development of post-thrombotic syndrome (PTS). Early removal of iliofemoral thrombosis by percutaneous mechanical thrombectomy (PMT) may reduce the incidence of PTS. There is currently a lack of research on which device is optimal for thrombus removal. The aim of this study is to conduct a multicenter, observational, prospective cohort study in patients with acute iliofemoral deep vein thrombosis (DVT), performing a head-to-head comparison of two different types of mechanical thrombectomy devices - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Studietype

Observasjonsmessig

Registrering (Antatt)

180

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Shanghai, Kina
        • Rekruttering
        • Renji Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

180

Beskrivelse

Inclusion Criteria:

  1. Aged between 18 and 85 years;
  2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;
  3. Time from symptom onset to endovascular treatment ≤ 14 days;
  4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;
  5. Patients sign the informed consent form.

Exclusion Criteria:

  1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;
  2. Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
  3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc.
  4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.
  5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.
  6. Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
  7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.
  8. Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or platelet count < 80,000/mL;
  9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
  10. Pregnant women;
  11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy < 24 months
  12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;
  13. Patients unwilling to participate in this trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
ClotTriever System group
Patients receive percutaneous mechanical thrombectomy by ClotTriever System
The procedure is performed via the ipsilateral popliteal vein access or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using stent retriever devices. Available stent retriever devices include currently marketed options such as ClotTriever (INARI MEDICAL, USA). After thrombectomy, the thrombus removal efficacy is assessed by venography.
Aspiration thrombectomy group
Patients receive percutaneous mechanical thrombectomy by aspiration or rheolytic thrombectomy
The procedure is performed via the ipsilateral calf deep vein access, the ipsilateral popliteal vein access, or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using mechanical aspiration thrombectomy devices. Available aspiration thrombectomy devices include currently marketed options such as the AngioJet thrombectomy catheter (Boston Scientific, USA) and the Acostream thrombectomy catheter (Acotec, China). After thrombectomy, the thrombus removal efficacy is assessed by venography.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of PTS
Tidsramme: At 24 months
Assessed by the Villalta score
At 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of moderate-to-severe PTS
Tidsramme: at 6, 12, and 24 months
Assessed by the Villalta score
at 6, 12, and 24 months
Clinical classification of Clinical-Etiology-Anatomy-Pathophysiology (CEAP)
Tidsramme: at 6, 12, and 24 months
Based on clinical symptoms
at 6, 12, and 24 months
Patency rate of the ipsilateral iliofemoral vein
Tidsramme: at 12 months and 24 months
Assessed by color Doppler ultrasound
at 12 months and 24 months
Incidence of PTS
Tidsramme: Assessed by the Villalta score
at 6 and 12 months
Assessed by the Villalta score
Recurrence rate of symptomatic Deep Vein Thrombosis (DVT)
Tidsramme: at 24 months
Assessed by symptoms combined with ultrasound examination in the ipsilateral limb
at 24 months
Rate of re-intervention
Tidsramme: at 24 months
Assessed by documentation of clinical reintervention
at 24 months
Quality of life score
Tidsramme: at 6, 12, and 24 months
Assessed by Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire (VEINES-QOL)
at 6, 12, and 24 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of major bleeding
Tidsramme: at 24 months
Defined by International Society on Thrombosis and Haemostasis (ISTH) criteria
at 24 months
Incidence of symptomatic Pulmonary Embolism (PE)
Tidsramme: at 24 months
Assessed by symptoms combined with contrast-enhanced computed tomography examination
at 24 months
Incidence of symptomatic Venous Thromboembolism (VTE)
Tidsramme: at 24 months
Assessed by symptoms combined with ultrasound and contrast-enhanced computed tomography examination
at 24 months
All-cause mortality
Tidsramme: at 24 months
All-cause death
at 24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2024

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

26. mai 2026

Først innsendt som oppfylte QC-kriteriene

26. mai 2026

Først lagt ut (Faktiske)

3. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere